AROA.F Stock Overview

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. More details

AROA.F fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 92.6% below our estimate of its fair value

Earnings are forecast to grow 60.69% per year

Earnings have grown 20.8% per year over the past 5 years

Analysts in good agreement that stock price will rise by 88.4%

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($152M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Aroa Biosurgery Limited Competitors

Caribou Biosciences

NasdaqGS:CRBU

US$79.1m

Surrozen

NasdaqCM:SRZN

US$93.5m

Sutro Biopharma

NasdaqGM:STRO

US$88.6m

OncoCyte

NasdaqCM:OCX

US$88.1m

Price History & Performance

Summary of share price highs, lows and changes for Aroa Biosurgery
Historical stock prices
Current Share Price	AU$0.24
52 Week High	AU$0.40
52 Week Low	AU$0.24
Beta	0.49
1 Month Change	-39.03%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-39.03%

Recent updates

Shareholder Returns

	AROA.F	US Biotechs	US Market
7D	0%	1.6%	2.7%
1Y	n/a	-4.5%	9.6%

Return vs Industry: Insufficient data to determine how AROA.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how AROA.F performed against the US Market.

Price Volatility

Is AROA.F's price volatile compared to industry and market?
AROA.F volatility
AROA.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.6%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	4.1%

Stable Share Price: AROA.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AROA.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Brian Ward	aroa.com

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds.

Aroa Biosurgery Limited Fundamentals Summary

How do Aroa Biosurgery's earnings and revenue compare to its market cap?
AROA.F fundamental statistics
Market cap	US$97.02m
Earnings (TTM)	-US$4.52m
Revenue (TTM)	US$45.27m

2.2x

P/S Ratio

-22.0x

P/E Ratio

Is AROA.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AROA.F income statement (TTM)
Revenue	NZ$76.35m
Cost of Revenue	NZ$10.21m
Gross Profit	NZ$66.15m
Other Expenses	NZ$73.76m
Earnings	-NZ$7.62m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

May 31, 2025

Earnings per share (EPS)	-0.022
Gross Margin	86.63%
Net Profit Margin	-9.98%
Debt/Equity Ratio	0%

How did AROA.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/01 23:53
End of Day Share Price	2025/04/07 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aroa Biosurgery Limited is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elyse Shapiro	Bell Potter
John Hester	Bell Potter
Elyse Shapiro	Canaccord Genuity

Aroa Biosurgery OTCPK:AROA.F Stock Report